Clinical Trial Update: A Relative Bioavailability Study of 75mg Indomethacin Extended-Release Capsules [Phase 1]

View source ↗

Summary

Sandoz conducted a Phase 1 study to compare the relative bioavailability of 75 mg indomethacin extended-release capsules. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammation

Drugs mentioned

• Indomethacin ER 75 mg capsules (indomethacin)

Snippet

Sponsor: Sandoz | Conditions: Inflammation | Phase 1 | Status: COMPLETED